GRM5 and fragile X syndrome: Larger studies with additional molecular biomarkers [93] are needed to expand on the feasibility finding of this protocol to evaluate the receptor expression of mGluR5s using [18F]FPEB as a helpful tool for the design of clinical trials of glutamatergic agents in FXS.